The 65th Meeting of the Expert Committee on Intractable Diseases, Health Sciences Council

News Highlights

The 65th meeting of the Expert Committee on Intractable Diseases, Health Sciences Council was held. From the perspective of medical M&A and business succession, third-party succession is suggested as a measure for successor issues. In particular, the importance of early consideration in 5-10 year increments, starting around age 60 for chairpersons and directors, was emphasized. The utilization of support organizations specializing in the medical industry is also recommended.

M&A Medical Editorial Department’s Perspective

The fact that “third-party succession” was suggested as an option for medical institution successor issues in a public forum like the Expert Committee on Intractable Diseases is extremely important for us medical M&A intermediaries. It can be said that public institutions have recognized this not just as a solution for a lack of successors, but as a concrete path to maintaining and developing the healthcare provision system, avoiding closure or廃業 (going out of business). The specific timeline of preparation starting around age 60 over a 5-10 year span will be an opportunity to change the perception of many medical institution managers who think “it’s still in the future.” The recommendation to utilize medical-specialized advisors is an indispensable element for smooth negotiations, appropriate valuation, and scheme construction in the M&A of highly specialized medical institutions, and it makes us reconfirm the importance of our role.

Points Raised by This News

• The mention of successor issues and third-party succession in a public forum discussing the designation of intractable diseases has the potential to promote a change in awareness regarding business succession throughout the industry.
• The presentation of a concrete timeline of preparation over a 5-10 year span starting around age 60 will encourage early action by managers.
• The recommendation to utilize advisors who understand the specificities of medical institutions will contribute to an increase in M&A closing rates.
• The significance of third-party succession being discussed in a public forum as an alternative to closure or business cessation is substantial.

Practical Questions Arising from This News

• What specific intractable diseases were discussed at this committee meeting?
• Is there more detailed information available on specific schemes and success stories of third-party succession?
• What are the selection criteria for medical-specialized advisors and what are their specific support services?

If You Feel “Should I Consult Too?”

If your institution’s chairperson or director is around 60 years old and the lack of a successor is a realistic issue, the message of “early consideration in a 5-10 year span” is not something to be taken lightly. If you wish to avoid closure or 廃業 (going out of business) and continue contributing to regional healthcare, it is time to consider consulting with experts familiar with medical M&A. Let’s start by organizing your institution’s current situation and future vision, and exploring the possibilities of third-party succession.

M&A Medical (CentralMedience Co., Ltd.) supports the business succession of medical corporations, hospitals, and clinics as a Small and Medium Enterprise Agency-certified M&A support institution, on a full success fee basis. We handle consultations with strict confidentiality. Free consultation here.